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The rate of arteriovenous ﬁstula (AVF) placement continues to rise and AVF failure is a major complication. The main cause
of AVF failure is stenosis leading to thrombosis. Although the detection of early stenosis with preemptive correction prior to
thrombosisseemstobeaplausibleoptiontopreventaccessfailure,thereismuchdebate,onthebasisofstudiesofsurveillancewith
arteriovenous grafts, as to whether early surveillance actually improves the longevity of AVFs. Evaluating the available information
for surveillance, speciﬁcally the data for AVF stenosis and survival, is necessary to determine if surveillance is warranted. These
trials have shown that vascular access ﬂow (Qa) surveillance is beneﬁcial in revealing subclinical stenosis. Preemptive angioplasty
and surgical revision have shown to decrease thrombosis rates. However, at the present time, there is only limited data on whether
preemptive treatment equates to improved long-term AVF survival.
1.Introduction
The occurrence of end-stage renal disease (ESRD) and
dialysis access placement in the United States continues to
increase [1]. Due to the superior long-term patency, lower
complications, and decreased mortality rates, arteriovenous
ﬁstulas (AVFs) are the access of choice and represent 41.3%
of the total hemodialysis accesses in the United States
[1, 2]. Even as the rate of ﬁstula placement improves,
hemodialysis access failure continues to be a leading cause
of hospitalizations and morbidity in the dialysis population
[1]. The development of signiﬁcant stenosis leading to poor
ﬂow and thrombosis is a leading cause of AVF revision
and failure [2]. Although the detection of early stenosis
with preemptive surgical correction or angioplasty prior to
thrombosis seems to be a plausible option to prevent access
failure, there is much debate as to whether early surveillance
actually improves the longevity of AVFs.
There are many noninvasive methods available for the
surveillance of stenosis (Table 1). Clinical monitoring is a
useful technique that involves physical examination of the
access site, excessive bleeding from the AVF venopuncture
site, diﬃcult cannulation, or unexplained reduction of urea
reduction ratio (URR). Other surveillance methods are
availableincludingaccessrecirculation,ﬂowstudies,pressure
studies and direct visualization by Doppler ultrasonography
[3]. These various methods of surveillance have been studied
and are all predictive of stenosis [4, 5]. This has led to
the guidelines by the National Kidney Foundation Dialysis
Outcomes Quality Initiatives (K/DOQI) advocating routine
surveillance of AVFs and arteriovenous grafts (AVGs) in
dialysis centers [6].
Surveillance of AVGs and AVFs is deﬁned separately by
the K/DOQI guidelines and studies have shown diﬀerent
results in these two distinct access groups [6]. In AVGs,
there has been considerable debate on the validity of surveil-
lance for thrombosis. Initial observational studies revealed
a reduction in graft thrombosis with routine surveillance
programs and preemptive angioplasty [7]. However, this
was not conﬁrmed by randomized controlled trials, as
surveillance and preemptive angioplasty failed to lower
thrombosis rates or improve long-term graft survival [7].
Therefore, the recommendation of routine surveillance for
AVGs [6]h a sb e e nq u e s t i o n e d[ 3].2 International Journal of Nephrology
Table 1: Noninvasive methods of surveillance for AV access
stenosis.
Clinical monitoring
Access recirculation
Flow studies
Sodium, urea, glucose, diﬀerential conductivity, inline
dialysance, ultrasound dilution and thermal methods
Pressure studies
Dynamic
Static
Direct visualization
Doppler ultrasonography
Magnetic resonance angiography
Debate also exists surrounding surveillance for AVFs
on eventual thrombosis or ﬁstula longevity. Measurement
of vascular access ﬂow (Qa) is the recommended method
of surveillance for AVFs, and much of this data is based
on the observational studies in AVGs [6]. There have
been numerous observational studies with historical control
groups evaluating the beneﬁt of Qa surveillance in AVFs,
and results have been mixed [8–13]. Few of these studies
[10–13] showed decreased thrombosis rates, while others
[8, 9] showed no improvement [14]. Evaluating the available
randomized controlled trials can better assess the question
of whether the use of surveillance leads to a signiﬁcant
decrease in the rate of AVF thrombosis and improves long-
term survival.
2. Randomized Controlled Trials
To date, there are four randomized trials that evaluated
surveillance of AVF for stenosis and two of these evaluated
the eﬀect of prophylactic angioplasty on thrombosis rates
and long-term outcomes (Table 2). In the most recent study,
investigators randomly assigned 137 patients with AVFs to
two groups: a group of monthly surveillance with Qa and
clinical criteria and a control group with clinical criteria
alone [15]. The clinical criteria consisted of an increase in
dynamic venous pressures, decrease in blood ﬂow (Qb),
excessive bleeding from venopuncture sites or unexplained
reduction in URR. The patients in the Qa surveillance arm
were referred to angiography if their Qa was <500mL/min
or if it fell by >20% once the access ﬂow was <1,000mL/min.
Each group was referred for any changes in clinical criteria.
The primary end point was time to detection of a stenotic
lesion that was ≥50%. Although thrombosis rates and AVF
longevity were not reported in this study, the patients in
the Qa surveillance arm were twice as likely to have stenosis
detected compared to the control group.
The more relevant outcome of thrombosis rates were
evaluated in a separate trial [16]. This study [16] included
103 patients of whom 68 had AVFs and 35 had AVGs. They
were randomized into two major groups: one with monthly
surveillance by Qa or static venous pressure and a control
group.AllpatientsunderwentcolorﬂowDopplerultrasound
every 6 months. Patients with Qa < 750mL/min or static
venous pressure ratios ≥0.5 were referred for angiography.
Using Doppler ultrasound, AVFs with >50% stenosis, Qa
< 600mL, or greater than 25% decline in Qa were also
referred for angiography. If there was evidence of a stenotic
lesion ≥50% of the vessel diameter, the patients underwent
angioplasty. The primary end point was AVF thrombosis.
Access longevity was not studied, but patients with AVFs
followed with monthly surveillance by Qa and/or static
venous pressure had a lower total thrombosis rate than the
control patients (16.8 versus 27.1per100 patient years; P<
0.05).
These studies revealed that surveillance using Qa detects
early stenosis and leads to decreased thrombosis rates, but
is there any long-term beneﬁt for early intervention in
patients with subclinical stenotic AVFs? This was evaluated
in a trial [17] that included 60 patients with a stenotic
lesion of >50% by angiogram who were randomized into a
treatment group that underwent percutaneous transluminal
angioplasty (PTA) or a control group with no intervention.
Patients were initially screened with measurements of blood
ﬂow (Qb decrease by >30mL/min on two consecutive
hemodialysis sessions), access ﬂow (Qa < 850mL/min) or
urea-based access recirculation. If there was an abnormality,
these patients were sent for ﬁstulography, and if >50%
stenosis was found, they underwent randomization. All the
AVFs with stenotic lesions were considered to be functional
if they were providing adequate dialysis. The study end
point was thrombosis or surgical revision due to inadequate
dialysis. Impressively, the median functional failure-free AVF
survival was 84 months (51.8 to 116.2 months) in the PTA
group and 21 months (9.8 to 32.2 months) in controls
(P< 0.001). A total of 6 patients in the PTA group
had thrombosis compared to 14 patients in the control
group (P = 0.029). However, the proportion of patients
undergoingelectivesurgerywascomparable.Therefore,early
intervention in stenotic AVFs led to decreased time to and
rates of thrombosis.
Surveillance of AVFs and early intervention has been
shown to be successful in detecting stenosis and preventing
thrombosis, but does identifying a signiﬁcant stenosis lead
to an increase in longevity of the access? A follow-up study
from the same institution was performed shortly after in
2004 [18]. This study design was similar to the prior study.
It included 79 patients with a signiﬁcantly stenotic lesion
who were randomized into treatment (PTA or surgical
revision) or control group. The stenotic lesion was identiﬁed
as in the above study with the only diﬀerence now being
aQ a< 750mL/min. One unique variation in the study
protocol was that the treatment and control group were
further divided into a “functional” (Qa > 350mL/min)
or “failing” (Qa ≤ 350mL/min) group. The primary end
point was primary patency as deﬁned by the interval from
stenosis to access failure. The primary patency rates were
higher in the treatment groups compared to the control
for both functional (P = 0.021) and failing subgroups
(P = 0.005). Access survival rates were signiﬁcantly higher
in the treatment group than the control group (P = 0.050).
Interestingly, within the treatment group, survival ratesInternational Journal of Nephrology 3
Table 2: Randomized controlled trials of arteriovenous ﬁstula surveillance.
Name Survey method
Preemptive
angioplasty/surgical
revison
Control group Treatment
group
Reduce
thrombosis
Prolong
survival
Polkinghorne et
al.[15]
Qa (<550mL/min) and Clinical
criteria versus Clinical criteria
alone
No 68 69 ∗∗
Sands et l. [16]
Qa (<800mL/min), Static venous
pressure and Doppler ultrasound
versus Doppler ultrasound alone
No 40 63 Yes ∗
Tessitore et al. [17] Qa (<850mL/min), Qb, Ru, and
Rhd Yes 30 32 Yes ∗
Tessitore et al. [18]Q a ( <750mL/min), Qb, and Ru Yes 36 43 Yes Yes
∗Data/values not reported or unavailable.
Qa: vascular access ﬂow, Qb: blood ﬂow, Ru: urea-based access recirculation, and Rhd: ultrasound dilution recirculation.
were also higher in the functional subgroup compared to
the failing one (P = 0.033). This study showed that early
intervention on stenotic AVFs leads to increased longevity.
If intervention is delayed until Qa ﬂow is too low, then the
AVF was not as salvageable with intervention.
When, then, is the appropriate time to intervene? Should
prophylactic correction of subclinical stenosis become uni-
versal when a low Qa is detected? The two trials that eval-
uated preemptive treatment of subclinical stenosis showed
decreased thrombosis rates [17, 18]. In both trials, the
majority of patients were sent to angiography, because their
Qa was <850mL/min or 750mL/min, further validating the
importance of using a surveillance program. The current
guidelinesrecommendcorrectiononlyinpoorly functioning
AVFs that are causing clinical compromise [6]. These trials
show that preemptive treatment of stenosis detected by
surveillance, prior to clinical consequences, is beneﬁcial and
in one trial [18], preemptive treatment was better when the
Qa > 350mL/min. Once the Qa became lower than this
threshold, the access was past the point of repair.
One of the major limitations of universally recom-
mending preemptive intervention is that there is a paucity
of information on long-term survival, as only one study
evaluated this [18]. Even in that study, over a quarter of
the treatment group underwent surgical revision as opposed
to PTA [19] that may have contributed to these AVFs
survivinglonger.Infact,onestudy[16]rev ealedanincreased
restenosis rate after PTA.
The key question of whether detection of stenosis and
early intervention increases the longevity of AVFs is unfortu-
nately still not answered. Even though thrombosis rates have
been lower in all studies, if there is no correlation to longer
AVF survival, the beneﬁcial eﬀect may be inconsequential.
If there is no beneﬁt of access survival with surveillance,
increased studies and interventions only consume more
resources and add to cost. The method of repair (PTA or
surgical) is also relevant. Although the available information
suggests a beneﬁt with surveillance, there needs to be larger,
powered randomized trials on the long-term survival of AVF
to conclusively settle the issue of the use of surveillance
leading to longer AVF survival.
3. Conclusion
Observationalstudieshaveshownmixedresultsfortheuseof
Qa surveillance in preventing AVF thrombosis. Randomized
controlled trials, though, have shown that Qa surveillance
is beneﬁcial in revealing subclinical stenosis. Preemptive
angioplasty and surgical revision have shown to decrease
thrombosis rates. Larger, randomized controlled trials need
to be done to show whether preemptive treatment equates to
improved long-term AVF survival.
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